Medical Design Briefs - January 2024 - 33

markers in microneedle-extracted ISF
samples with 100 to 1000-fold increased
sensitivities compared to commonly
used assays, and the measurements mirrored
parallel Simoa measurements of
the same biomarkers in blood samples.
" It was striking to see that animals with
the most pronounced pro-inflammatory
response were also those that survived
the longest, " says Dahis.
Other authors on the study are Michelle
Dion, Alexander Cryer, Pere
Dosta, Mariana Alonso, Michael Lewandowski,
Núria Puigmal, Gonzalo
Muños Taboada, and Haim Azhari.
The study was supported by the Technion
Institute of Technology, the MITIsrael
Zuckerman STEM Fund (under
award# 2214110), the Technion Integrated
Cancer Center, the Wyss Institute's
Diagnostic Accelerator (DxA),
and a Binational Science Fund-Prof.
Rahamimoff Travel grant, as well as a
Weizmann Institute of Science Women's
Development Award.
This article was written by Benjamin
Boettner, Harvard University. For more
information, contact Natalie Artzi, PhD,
at nartzi@bwh.harvard.edu
https://wyss.harvard.edu.
Bioink Enhances 3D Bioprinted Skeletal Muscle Constructs
The microparticles are
engineered for sustained
delivery IGF-1.
Terasaki Institute
Los Angeles, CA
An advancement in 3D bioprinting of
native-like skeletal muscle tissues has been
made by scientists at the Terasaki Institute
for Biomedical Innovation (TIBI). The
key to the TIBI scientists' approach lies in
their specially formulated bioink, which
contains microparticles engineered for
sustained delivery of insulin-like growth
factor-1 (IGF-1).
As was shown in their recent paper in
Macromolecular Bioscience, sustained
delivery of IGF-1 enhances the formation
of mature skeletal muscle tissue
from muscle precursor cells and facilitates
their structural alignment. This increases
the efficiency of the regenerative
process and can lead to successful therapies
for people suffering from muscle
loss or injury.
The loss of skeletal muscle due to
trauma, disease, or surgical procedures
results not only in functional impairment
but causes damage to associated
tissues, such as blood vessels and other
structural tissues. Current treatment
for such muscle loss is the transfer of a
patient's healthy muscle tissue from a
different site to the injury site. However,
or visit
Your first source.
Your second source.
The only source you need.
Partner with Qosina and let us help you find
the most suitable component for your project.
We offer many options of similar products to meet
your required specifications. We also provide
downloadable documentation and complimentary
samples for testing and evaluation.
Log on to qosina.com today to see our full product offering.
qosina.com
Qosina Corp.:
Qosina Europe:
+1 631 242-3000
info@qosina.com
qosina.com/qosina-europe
+39 02 66401337
info@qosinaeurope.com
Medical Design Briefs, January 2024
www.medicaldesignbriefs.com
33
https://wyss.harvard.edu http://info.hotims.com/86251-748 http://info.hotims.com/86251-748 http://www.medicaldesignbriefs.com
Medical Design Briefs - January 2024

Table of Contents for the Digital Edition of Medical Design Briefs - January 2024
